Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

MorphoSys Receives Centocor Milestone Payment

December 22, 2010 7:14 am | News | Comments

MorphoSys AG has received a clinical milestone payment from Centocor Ortho Biotech Inc. for a clinical trial application for a phase 1 clinical trial of a HuCAL-derived antibody in the therapeutic area of inflammatory and autoimmune diseases.


Cancer Stem Cells Bode Poor Prognosis

December 22, 2010 6:53 am | News | Comments

Researchers have found that leukemia patients whose cancers express higher levels of genes associated with cancer stem cells have a significantly poorer prognosis than patients with lower levels of the genes.


CTCs Related to Worse Outcomes in Head/Neck Cancer

December 22, 2010 6:49 am | News | Comments

A study suggests that the presence of tumor cells in the circulating blood of patients with squamous cell cancer of the head and neck may predict disease recurrence and reduced survival; it also correlates with a worse outcome.


AMR-001 Demonstrates Effectiveness in AMI

December 22, 2010 6:43 am | News | Comments

The American Heart Journal reported results of a clinical trial evaluating Amorcyte, Inc.’s lead product candidate, AMR-001 for the treatment of damaged heart muscle following acute myocardial infarction.


Tekmira Begins Phase 1 Cancer Trial

December 22, 2010 6:38 am | News | Comments

Tekmira Pharmaceuticals Corporation, a developer of RNA interference therapeutics, announced it has initiated patient dosing in a Phase 1 human clinical trial for its lead oncology product, TKM-PLK1.


Biogen And Elan to Update Tysabri Info

December 22, 2010 6:36 am | News | Comments

Biogen Idec and Elan Corp. said they have applied to U.S. and European regulators to update prescribing information for the multiple sclerosis drug Tysabri to help classify the risk of a rare but serious brain infection.


Ligand to Receive $1M from Pfizer

December 22, 2010 6:34 am | News | Comments

Ligand Pharmaceuticals Inc. said it will receive a $1 million payment from Pfizer Inc. as part of a partnership for the potential contraceptive Tanaproget.


Pfizer Settles Breast Cancer Lawsuits

December 22, 2010 6:33 am | News | Comments

Two pharmaceutical companies have agreed to a settlement with two Nevada women who claimed hormone replacement drugs caused their breast cancer.


Teva to Sell Generic Actos

December 22, 2010 6:31 am | News | Comments

Teva Pharmaceutical Industries Ltd. said it will start selling a generic version of the diabetes drug Actos after settling a patent infringement lawsuit brought by the company that makes Actos, Takeda Pharmaceutical Co.


Vertex Halts Part of HCV Trial

December 22, 2010 6:30 am | News | Comments

Vertex Pharmaceuticals Inc. said it stopped part of a midstage clinical study evaluating a combination of two hepatitis C drugs. The company said the combination of telaprevir and VX-222 was not working.


FDA Rejects Acetadote Expanded Use

December 22, 2010 6:28 am | News | Comments

Cumberland Pharmaceuticals Inc. said the Food and Drug Administration rejected the company's request to expand approval for the liver failure drug Acetadote.


Arena Reapplying for Approval of Lorcaserin

December 22, 2010 6:27 am | News | Comments

Arena Pharmaceuticals Inc. said it plans to again ask the Food and Drug Administration to approve its experimental weight-loss drug lorcaserin by the end of 2011, following the agency's recent rejection over safety concerns.


ZFN Kits

December 21, 2010 7:01 am | Product Releases | Comments

SAFC announced an extension to Sigma-Aldrich's proprietary CompoZr Zinc Finger Nuclease platform that will expand ZFN-based technology to include off-the-shelf ZFNs and custom cell engineering services for use in the biopharmaceutical industry.


Protein Assay

December 21, 2010 6:51 am | Product Releases | Comments

The NI (Non-Interfering) Protein Assay is a highly sensitive colorimetric protein assay that overcomes interference of common laboratory agents present in protein solutions.


CHMP Recommends Teysuno for Gastric Cancer

December 21, 2010 6:34 am | News | Comments

Taiho Pharmaceutical Co., Ltd. announced that the Committee for Medicinal Products for Human Use has recommended approval of Teysuno, a novel oral anti-cancer agent, for treatment in adults with advanced gastric cancer when given in combination with cisplatin.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.